Co-discovery and co-development of nanobodies
27-Sep-2013
- Germany
Merck Serono and Ablynx announced that they have further expanded their relationship through a multi-year research alliance that could lead to several co-discovery and co-development collaborations.
Under the terms of the agreement, Merck Serono will fund a dedicated discovery group at Ablynx. Both partners will jointly select disease targets against which this group will develop Nanobodies®, up to in vivo proof-of-principle. The dedicated group will focus on the discovery and development of Nanobodies against a number of targets across multiple disease areas. The collaboration will span all of Merck Serono’s core research and development fields, including oncology, immuno-oncology, immunology and neurology.
Other news from the department science
